Sub-clinical glutamate receptor antagonist combinations prevent progressive demyelination.
Verity F. T. Mitchener, Chris Bulman, Alexander Mellor, Nishita Bhatt, Badrah Saeed Ali Alghamdi, Jackie Nash, Rhianon Proctor, Nancy Smith, Abbie Newman, Victoria Nwabiakam, Gideon Stone, Daniel Morgan, Waldemar Woznica, Glenn M. Harper, Mario Valentino, , Robert F. Fern
The paper shows that sub-clinical doses of NMDA and AMPA glutamate receptor antagonists protect against demyelination in experimental models of multiple sclerosis.
bioRxiv · Mar 19, 2024 · PreprintNeuroscience